High rates of overall response and MRD negativity were seen regardless of the dose patients received, said Andrew Spencer, MBBS.
Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...
GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...
LONDON, UK I 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from a planned interim analysis of the DREAMM-7 ...
Multiple Myeloma, a cancer of the plasma cells in the bone marrow, is the third most common blood cancer in Europe. Despite recent advanced in treatment that has increased survival, it is still an ...
Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...
Healthcare Asia on MSN15h
Pharmaceutical firms eye multiple myeloma amidst rising incidence ratesThe increase has been faster in women since 2000. The rising incidence of multiple myeloma (MM), particularly in relapsed and ...
She was born December 16, 1962, in Cape Girardeau to Robert and Nancy Kent Littleton. She and Stephen Puchbauer were married ...
On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback